Abstract
Nanocarriers are effective non-viral vectors for drug and gene delivery with low immunogenicity in comparison with viral vectors. However, the lack of organ or cell specificity sometimes hinders their application and brings about unexpected side effects. Active targeting is an outstanding strategy recently developed for drug delivery systems, for example, surface modification of nanocarriers with specific ligands could target the pathological area to provide the maximum therapeutic efficacy. In such cases, the characteristics of the ligands determine the active targeting abilities of the nanocarrier systems. Recently, more attentions have been paid to saccharides as ligands for saccharidemodified nanocarriers, possesing the receptor-mediated targeting properties and showing the potential for cell-specific delivery of drugs and genes. In this review, various kinds of glycosylated nanocarriers are discussed, including: varying ligands, targeting properties, therapeutic effects, and methods for administering the nanocarriers. The advantages as well as the probable associated drawbacks of these vectors are communicated.
Keywords: Nanocarriers, surface modification, saccharide ligands, active targeting, drug and gene delivery
Current Pharmaceutical Design
Title: Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery
Volume: 15 Issue: 32
Author(s): Wangyang Yu, Na Zhang and Changjun Li
Affiliation:
Keywords: Nanocarriers, surface modification, saccharide ligands, active targeting, drug and gene delivery
Abstract: Nanocarriers are effective non-viral vectors for drug and gene delivery with low immunogenicity in comparison with viral vectors. However, the lack of organ or cell specificity sometimes hinders their application and brings about unexpected side effects. Active targeting is an outstanding strategy recently developed for drug delivery systems, for example, surface modification of nanocarriers with specific ligands could target the pathological area to provide the maximum therapeutic efficacy. In such cases, the characteristics of the ligands determine the active targeting abilities of the nanocarrier systems. Recently, more attentions have been paid to saccharides as ligands for saccharidemodified nanocarriers, possesing the receptor-mediated targeting properties and showing the potential for cell-specific delivery of drugs and genes. In this review, various kinds of glycosylated nanocarriers are discussed, including: varying ligands, targeting properties, therapeutic effects, and methods for administering the nanocarriers. The advantages as well as the probable associated drawbacks of these vectors are communicated.
Export Options
About this article
Cite this article as:
Yu Wangyang, Zhang Na and Li Changjun, Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery, Current Pharmaceutical Design 2009; 15 (32) . https://dx.doi.org/10.2174/138161209789649547
DOI https://dx.doi.org/10.2174/138161209789649547 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry Protective Effect of Zinc on Mouse Renal Ischemia-reperfusion Injury by Anti-apoptosis and Antioxidation
Current Pharmaceutical Biotechnology Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Potential Repurposing of Drugs with Anti-SARS-CoV-2 Activity in Preclinical Trials: A Systematic Review
Current Medicinal Chemistry Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets Oxidative stress and myocarditis
Current Pharmaceutical Design Meet the Editorial Board:
Current Drug Targets Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Current Drug Targets Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Neuroprotective Effects of Heat Shock Protein70
CNS & Neurological Disorders - Drug Targets Kinase Inhibitor Conjugates
Current Pharmaceutical Design Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design